We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

000513:SZSELivzon Pharmaceutical Group Inc. Analysis

Data as of 2026-09-06 - not real-time

CN¥26.77

Latest Price

5/10Risk

Risk Level: Medium

Executive Summary

Livzon Pharmaceutical Group Inc. trades at ¥26.77, with its short-term moving averages sitting below the longer-term ones — a bearish trend structure. Over a rolling month the price has lost 10.6%. With RSI at 35.4 the momentum picture is approaching oversold, alongside a bearish MACD signal. Recent trading has carved out support near ¥25.74 and resistance around ¥31.27.
The shares look undervalued, trading on 14.2 times earnings below a sector average of 30.6. The average analyst target implies 27.1% above today's level. Revenue is contracting at 31.1% on a 15.6% profit margin. The 5.34% dividend yield looks covered by current payout levels.
The composite risk read is 5/10, putting it in moderate territory. With 30-day volatility of 37.9%, a beta of 0.07 and a maximum drawdown of 37.6%, position sizing matters here. The wider market backdrop reads extreme greed at 95 on the fear-greed composite.
This one splits by horizon — hold in the near term, buy further out, at 5/10 long-term conviction.

Top Market Events

Investing28dLivzon Pharmaceutical Group IncWe've identified the following companies as similar to Livzon Pharmaceutical...

Market Outlook

Short Term

< 1 year
Neutral
Model confidence: 3/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • Trading below the 200-day average of 32.90
  • MACD momentum is negative

Medium Term

1–3 years
Neutral
Model confidence: 2/10

Key Factors

  • Short-term moving averages stacked below long-term ones
  • P/E of 14.2 versus sector average of 30.6
  • Trading below the 200-day average of 32.90

Long Term

> 3 years
Positive
Model confidence: 5/10

Key Factors

  • P/E of 14.2 versus sector average of 30.6
  • Analyst targets imply +27.1% versus the current price
  • Profit margin of 15.6% is healthy

Key Metrics & Analysis

Financial Health

Revenue Growth-31.10%
Profit Margin15.58%
P/E Ratio14.2
ROE13.42%
ROA5.93%
Debt/Equity23.68
P/B Ratio1.8
Op. Cash FlowCN¥3.2B
Free Cash FlowCN¥2.1B
Industry P/E30.6

Technical Analysis

TrendBearish
RSI35.4
SupportCN¥25.74
ResistanceCN¥31.27
MA 20CN¥28.36
MA 50CN¥29.67
MA 200CN¥32.90
MACDBearish
VolumeStable
Fear & Greed Index95.48

Valuation

Fair ValueCN¥35.51
Target PriceCN¥34.04
Upside/Downside27.15%
GradeUndervalued
TypeValue
Dividend Yield5.34%

Risk Assessment

Beta0.07
Volatility37.92%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.